Rua Life Sci. Regulatory News (RUA)

30 December 2020

RUA Life Sciences plc

(the "Company" or the "Group")

Results of General Meeting

Total Voting Rights

Director/PDMR Dealings

RUA Life Sciences plc (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon™, a long-term implantable biostable polymer, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders. 

Furthermore, as announced earlier today the Open Offer closed for acceptances at 11.00 a.m. on 29 December 2020 with final valid applications from Qualifying Shareholders in respect of 831,522 Open Offer Shares. Qualifying Shareholders who have validly applied for Open Offer Shares have received their full Open Offer Entitlement. Applications made under the Excess Application Facility were oversubscribed and have been scaled back pro-rata such that approximately 9.7 per cent. of the Excess Application is satisfied.

Accordingly, the Company will raise a total of approximately £7.0 million (before expenses) through the Placing, Subscription and Open Offer and has thus issued and allotted 5,831,522 New Ordinary Shares. An application has been made for the 5,831,522 New Ordinary Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 31 December 2020.

The net proceeds of the Placing, Subscription and Open Offer will be used by the Company primarily to fund the acceleration of the Group's surgical heart valve through to human trials, to accelerate development of the Company's TAVI valve, to scale up the Group's graft manufacture to meet anticipated demand and to allow further investment in capital equipment to assist in the scale up of the Group's capacity.

Following Admission, the Company's issued share capital will comprise 22,184,797 Ordinary Shares, of which none are held in treasury, and 4,832,778 Deferred Shares which carry no voting rights. The above figure of 22,184,797 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

John Ely, a Non-Executive Director of the Company and Anthea Berg, a Person Closely Associated with Geoffrey Berg, a Non-Executive Director of the Company, have subscribed for New Ordinary Shares through the Subscription as detailed below.

* following Admission

** Application made in the name of Anthea Berg, wife of Geoffrey Berg

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to Shareholders on 11 December 2020.

For more information please contact:

About RUA Life Sciences plc

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon™, widely accepted as being the most biostable of all long-term implantable polyurethanes.

Whether it is licensing Elast-Eon™, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, the Group's polymers are proven in long-term life enabling applications.

The Group's four business units are: